Quadrant Capital Group LLC Sells 15,329 Shares of Pfizer Inc. (NYSE:PFE)

Quadrant Capital Group LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 26.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,974 shares of the biopharmaceutical company’s stock after selling 15,329 shares during the period. Quadrant Capital Group LLC’s holdings in Pfizer were worth $1,140,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer during the 4th quarter valued at $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the 4th quarter worth approximately $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer during the fourth quarter valued at $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 5.4 %

Shares of NYSE:PFE opened at $22.99 on Monday. The company has a market cap of $130.39 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $31.54. The firm’s 50-day simple moving average is $25.87 and its 200-day simple moving average is $26.72. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 EPS. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PFE. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.